American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

Gastroenterology

Volumn 148, Issue 1, 2015, Pages 215-219

  Reddy, K Rajender ^a   Beavers, Kimberly L ^b   Hammond, Sarah P ^c   Lim, Joseph K ^d   Falck Ytter, Yngve T ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; NUCLEOSIDE ANALOG; VIRUS DNA; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MIXED INFECTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; TREATMENT INDICATION; VIRUS REACTIVATION; BLOOD; DRUG EFFECTS; GENETICS; IMMUNOLOGY; PATHOGENICITY; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84922953411     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.10.039     Document Type: Article

References (4)

1. American Gastroenterological Association. AGA Institute clinical practice guideline development process. January 2013. http://www.gastro.org/practice/medical-position-statements/aga-institute-clinical-practice-guideline-development-process.
2. S. Sultan, Y. Falck-Ytter, and J.M. Inadomi The AGA Institute process for developing clinical practice guidelines part one: grading the evidence Clin Gastroenterol Hepatol 11 2013 329 332
3. Institute of Medicine Clinical practice guidelines we can trust 2011 Institute of Medicine Washington, DC
4. R.P. Perrillo, R. Gish, and Y.T. Falck-Ytter American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 2015 221 244